(Q38876358)

English

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

scientific article published on 31 March 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

vector-borne disease

0 references

0 references

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

3

object named as

Omu Anzala

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Pontiano Kaleebu

35

object named as

Pontiano Kaleebu

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

6

object named as

Annet Nanvubya

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1

object named as

Walter Jaoko

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Andrew James McMichael

33

object named as

Andrew McMichael

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Emmanuel Mugisha

18

object named as

Emmanuel Mugisha

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Frederick N Nakwagala

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Gloria Omosa Manyonyi

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Josephine Birungi

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Farah Bashir

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Kirana Bhatt

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Hilda Ogutu

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sabina Wakasiaka

10

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Lucy Matu

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Wambui Waruingi

12

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jane Odada

13

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Micah Oyaro

14

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jackton Indangasi

15

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jeckonia Ndinya-Achola

16

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Carol Konde

17

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Patricia Fast

19

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Claudia Schmidt

20

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jill Gilmour

21

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Tony Tarragona

22

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Carol Smith

23

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Burc Barin

24

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Len Dally

25

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Bruce Johnson

26

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Andrew Muluubya

27

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Leslie Nielsen

28

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Peter Hayes

29

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Mark Boaz

30

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Peter Hughes

31

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Tomás Hanke

32

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Job Bwayo

34

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

31 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

2788-2795

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

HIV type 1 subtypes among STI patients in Nairobi: a genotypic study based on partial pol gene sequencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

First trial of the HIV-1 vaccine in Africa: Ugandan experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Assuring the quality, safety, and efficacy of DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

DNA vaccines against human immunodeficiency virus type 1 in the past decade

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Electroporation for targeted gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Epidermal delivery of protein and DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.071

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.02.071

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38876358&oldid=1879132143"